Innate Immune Mechanisms in Emphysema
Innate Immune Mechanisms in Emphysema
批准号:
8242027
负责人:
PATTY J LEE
金额:
$40.96万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-04-01 至 2014-09-30
关键词:
AgeAge-MonthsAgingAging-Related ProcessArchitectureBone MarrowBreedingCellsChemicalsChimera organismChronicChronic Obstructive Airway DiseaseCigaretteComplexDataDepressed moodDiseaseElasticityElementsEndothelial CellsEnvironmentEpithelialEpitheliumExposure toGene ExpressionGenerationsGoalsHumanImmuneLeadLifeLigandsLungLung diseasesMediatingMessenger RNAMusNADPH OxidaseOxidantsPathogenesisPathway interactionsPatientsPhenotypePulmonary EmphysemaReportingRoleSeveritiesSmall Interfering RNASmokerSmokingStructureTLR4 geneTestingToll-like receptorsTransgenic Miceairway epitheliumattenuationcell typecigarette smokingcigarette smokingclinically significanteffective therapyin vivoinhibitor/antagonistlung developmentnew therapeutic targetnormal agingnoveloverexpressionpathogenpollutantpreventreconstitutionresponse
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
Toll-like receptors (TLRs) have been studied extensively in the context of pathogen challenges, yet their role in
the unchallenged lung is unclear. Elucidating the mechanisms whereby the lung maintains structural integrity in
the face of complex external and internal environments is essential to our understanding of lung disease.
Emphysema is characterized by gradual loss of lung elasticity and irreversible airspace enlargement, occurring
to a certain extent in the normal aging process but pathologically accelerated with chronic exposure to
pollutants or cigarette smoke. The fact that only 10 to 20% of smokers develop clinically significant
emphysema indicates that other factors are important to its pathogenesis. Recent human studies indicate that
depressed TLR4 function is correlated with the severity of COPD, which lends human relevance to our finding
that TLR4-/- mice develop spontaneous emphysema after 2 months of age, when lung development is
complete. We found that TLR4 deficiency induces a novel NADPH oxidase (Nox), Nox3, and excessive oxidant
generation, also a feature of human emphysema. Treatment of TLR4-/- mice or lung endothelial cells with Nox
inhibitors or Nox3 siRNA reversed the phenotype. We generated inducible, lung-targeted Nox3 transgenic mice
that develop emphysema and also detected elevated Nox3 levels in patients with COPD, indicating an
important role for Nox3 in the pathogenesis of emphysema in vivo. In order to investigate the cell type
responsible for these TLR4-mediated responses, we generated bone marrow chimeras and found that TLR4
expression on non-hematopoietic cells is required to maintain normal lung architecture. Reconstitution of TLR4
to the airway epithelium only partially prevented emphysema in TLR4-/- and did not suppress Nox3 expression
or oxidant generation, indicating that TLR4 in an alternative structural cell is also involved in regulating lung
oxidants. Our data using primary lung endothelial cells point to an important role for endothelial TLR4, which
we will explore in this proposal. Our hypothesis is that endothelial TLR4 maintains lung integrity by suppressing
Nox3-mediated oxidant generation. We will test this hypothesis in the following Aims: 1) Determine the specific
contribution of endothelial TLR4 in preventing oxidant-mediated emphysema in vivo, 2) Elucidate the
mechanisms whereby TLR4 inhibits Nox3 gene expression in endothelial cells, and 3) Characterize the TLR4
ligand(s) involved in inhibiting Nox3 expression and preventing oxidant-mediated emphysema in vivo and in
lung endothelial cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Duke Program of Training in Pulmonary ReSearch to Promote, Engage and Retain Academic Researchers (PROSPER)
-
批准号:10332249
-
项目类别:
-
资助金额:$55.26万
-
财政年份:2022
-
负责人:PATTY J LEE
-
依托单位:
Vasculata 2022
-
批准号:10469215
-
项目类别:
-
资助金额:$4.2万
-
财政年份:2022
-
负责人:PATTY J LEE
-
依托单位:
Administrative Core
-
批准号:10376565
-
项目类别:
-
资助金额:$38.64万
-
财政年份:2021
-
负责人:PATTY J LEE
-
依托单位:
Administrative Core
-
批准号:10492747
-
项目类别:
-
资助金额:$33.84万
-
财政年份:2021
-
负责人:PATTY J LEE
-
依托单位:
The Duke Senescent Cell Evaluations in Normal Tissues (SCENT) Mapping Center
-
批准号:10376564
-
项目类别:
-
资助金额:$270.89万
-
财政年份:2021
-
负责人:PATTY J LEE
-
依托单位:
Administrative Core
-
批准号:10689776
-
项目类别:
-
资助金额:$33.84万
-
财政年份:2021
-
负责人:PATTY J LEE
-
依托单位:
ShEEP Request for KEYENCE BZ-X800 All-in-One Fluorescence Microscope
-
批准号:10177103
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:PATTY J LEE
-
依托单位:
TLR4-MEDIATED EPIGENETIC AND SENESCENCE MECHANISMS IN EMPHYSEMA
-
批准号:10013285
-
项目类别:
-
资助金额:$29.13万
-
财政年份:2017
-
负责人:PATTY J LEE
-
依托单位:
MIF-mediated Mechanisms in Emphysema
-
批准号:10083682
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2017
-
负责人:PATTY J LEE
-
依托单位:
MIF-mediated Mechanisms in Emphysema
-
批准号:10053820
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2017
-
负责人:PATTY J LEE
-
依托单位:
TLR4-MEDIATED EPIGENETIC AND SENESCENCE MECHANISMS IN EMPHYSEMA
-
批准号:9981929
-
项目类别:
-
资助金额:$32.68万
-
财政年份:2017
-
负责人:PATTY J LEE
-
依托单位:
TLR4-mediated Epigenetic and Senescence Mechanisms in Emphysema
-
批准号:9365438
-
项目类别:
-
资助金额:$41.88万
-
财政年份:2017
-
负责人:PATTY J LEE
-
依托单位:
Innate Immune Mechanisms in Emphysema
-
批准号:7655577
-
项目类别:
-
资助金额:$41.58万
-
财政年份:2009
-
负责人:PATTY J LEE
-
依托单位:
Innate Immune Mechanisms in Emphysema
-
批准号:7781292
-
项目类别:
-
资助金额:$41.38万
-
财政年份:2009
-
负责人:PATTY J LEE
-
依托单位:
Innate Immune Mechanisms in Emphysema
-
批准号:8055997
-
项目类别:
-
资助金额:$41.38万
-
财政年份:2009
-
负责人:PATTY J LEE
-
依托单位:
Innate Immune Mechanisms in Emphysema
-
批准号:7822503
-
项目类别:
-
资助金额:$1.59万
-
财政年份:2009
-
负责人:PATTY J LEE
-
依托单位:
Heme Oxygenase-1 in Lung Ischemia-Reperfusion Injury
-
批准号:8254391
-
项目类别:
-
资助金额:$40.96万
-
财政年份:2004
-
负责人:PATTY J LEE
-
依托单位:
Heme Oxygenase-1 in Lung Ischemia-Reperfusion Injury
-
批准号:7194243
-
项目类别:
-
资助金额:$32.78万
-
财政年份:2004
-
负责人:PATTY J LEE
-
依托单位:
Heme Oxygenase-1 in Lung Ischemia-Reperfusion Injury
-
批准号:6877749
-
项目类别:
-
资助金额:$34.7万
-
财政年份:2004
-
负责人:PATTY J LEE
-
依托单位:
Heme Oxygenase-1 in Lung Ischemia-Reperfusion Injury
-
批准号:7028892
-
项目类别:
-
资助金额:$33.83万
-
财政年份:2004
-
负责人:PATTY J LEE
-
依托单位: